JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

This study is testing a drug called JS203 — a type of bispecific antibody that directs immune cells to attack cancer — in combination with other treatments for people with B-cell non-Hodgkin's lymphoma (a type of blood cancer affecting immune cells called B-cells) that has come back or stopped responding to treatment. **You may be eligible if...** - You are between 18 and 80 years old - You have confirmed B-cell non-Hodgkin's lymphoma expressing the CD20 protein - You have at least one measurable area of cancer on imaging - Your overall health is acceptable (ECOG 0–2) and organ function meets study requirements **You may NOT be eligible if...** - You have a severe allergy to monoclonal antibody therapies - You have previously received a CD20-CD3 bispecific antibody - You have had a bone marrow or organ transplant - You have a history of autoimmune disease, macrophage activation syndrome, or progressive multifocal leukoencephalopathy (a rare brain infection) - Your cancer has spread to the brain or central nervous system Talk to your doctor to see if this trial is right for you.